- Home
- SEPN vs HRTX Comparison
SEPN vs HRTX Comparison
Compare SEPN & HRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEPN
- HRTX
- Stock Information
- Founded
- SEPN 2022
- HRTX 1983
- Country
- SEPN United States
- HRTX United States
- Employees
- SEPN N/A
- HRTX N/A
- Industry
- SEPN
- HRTX Biotechnology: Pharmaceutical Preparations
- Sector
- SEPN
- HRTX Health Care
- Exchange
- SEPN NYSE
- HRTX Nasdaq
- Market Cap
- SEPN 311.6M
- HRTX 325.0M
- IPO Year
- SEPN 2024
- HRTX 1987
- Fundamental
- Price
- SEPN $9.25
- HRTX $1.88
- Analyst Decision
- SEPN Buy
- HRTX Strong Buy
- Analyst Count
- SEPN 4
- HRTX 2
- Target Price
- SEPN $27.00
- HRTX $5.50
- AVG Volume (30 Days)
- SEPN 2.6M
- HRTX 2.1M
- Earning Date
- SEPN 05-15-2025
- HRTX 05-06-2025
- Dividend Yield
- SEPN N/A
- HRTX N/A
- EPS Growth
- SEPN N/A
- HRTX N/A
- EPS
- SEPN N/A
- HRTX N/A
- Revenue
- SEPN $977,000.00
- HRTX $148,518,000.00
- Revenue This Year
- SEPN N/A
- HRTX $12.60
- Revenue Next Year
- SEPN N/A
- HRTX $13.66
- P/E Ratio
- SEPN N/A
- HRTX N/A
- Revenue Growth
- SEPN 108.76
- HRTX 12.43
- 52 Week Low
- SEPN $4.17
- HRTX $1.04
- 52 Week High
- SEPN $28.99
- HRTX $3.93
- Technical
- Relative Strength Index (RSI)
- SEPN N/A
- HRTX 44.20
- Support Level
- SEPN N/A
- HRTX $1.82
- Resistance Level
- SEPN N/A
- HRTX $1.93
- Average True Range (ATR)
- SEPN 0.00
- HRTX 0.11
- MACD
- SEPN 0.00
- HRTX -0.01
- Stochastic Oscillator
- SEPN 0.00
- HRTX 36.73
About SEPN SEPTERNA INC
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.